Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Systematic Reviews
Published in: Systematic Reviews 1/2019

Open Access 01-12-2019 | Naloxone | Protocol

Naloxone interventions in opioid overdoses: a systematic review protocol

Authors: Lindsay Victoria Shaw, Jessica Moe, Roy Purssell, Jane A. Buxton, Jesse Godwin, Mary M. Doyle-Waters, Penelope M. A. Brasher, Jeffrey P. Hau, Jason Curran, Corinne M. Hohl

Published in: Systematic Reviews | Issue 1/2019

Login to get access

Abstract

Background

North America is in the midst of an unabated opioid overdose epidemic due to the increasing non-medical use of fentanyl and ultra-potent opioids. Naloxone is an effective antidote to opioid toxicity, yet its optimal dosing in the context of fentanyl and ultra-potent opioid overdoses remains unknown. This review aims to determine the relationship between the first empiric dose of naloxone and reversal of toxicity, adverse events, and the total cumulative dose required among patients with undifferentiated opioid overdoses and those with suspected toxicity from ultra-potent opioids. Secondary objectives include evaluating the relationship between the cumulative naloxone dose and toxicity reversal and adverse events, among patients with undifferentiated opioid overdoses and those with suspected toxicity from ultra-potent opioids.

Methods

To identify studies, we will search MEDLINE, Embase, CENTRAL, DARE, CDAG, CINAHL, Science Citation Index, multiple trial registries, and the gray literature. Included studies will evaluate patients with suspected or confirmed opioid toxicity from undifferentiated opioids and ultra-potent opioids, who received an empiric and possibly additional doses of naloxone. The main outcomes of interest are the relationship between naloxone dose and toxicity reversal and adverse events. We will include controlled and non-controlled interventional studies, observational studies, case reports/series, and reports from poison control centers. We will extract data and assess study quality in duplicate with discrepancies resolved by consensus or a third party. We will use the Downs and Black and Cochrane risk of bias tools for observational and randomized controlled studies. If we find sufficient variation in dose, we will fit a random effects one-stage model to estimate a dose-response relationship. We will conduct multiple subgroup analyses, including by type of opioid used and by suspected high and low prevalence of ultra-potent opioid use based on geographic location and time of the original studies.

Discussion

Our review will include the most up-to-date available data including ultra-potent opioids to inform the current response to the opioid epidemic, addressing the limitations of recent reviews. We anticipate limitations relating to study heterogeneity. We will disseminate study results widely to update overdose treatment guidelines and naloxone dosing in Take Home Naloxone programs.
Appendix
Available only for authorised users
Literature
1.
2.
Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2):S133–53.PubMed
3.
4.
5.
van Dorp ELA, Yassen A, Dahan A. Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf. 2007;6(2):125–32.PubMedCrossRef
6.
Wise RA, Bozarth MA. Brain mechanisms of drug reward and euphoria. Psychiatr Med. 1985;3(4):445–60.PubMed
7.
Volkow ND, McLellan AT. Opioid abuse in chronic pain - misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253–63.PubMedCrossRef
8.
Fischer B, Jones W, Rehm J. Trends and changes in prescription opioid analgesic dispensing in Canada 2005-2012: an update with a focus on recent interventions. BMC Health Serv Res. 2014;14:90.PubMedPubMedCentralCrossRef
9.
Gomes T, Mamdani MM, Dhalla IA, Cornish S, Paterson JM, Juurlink DN. The burden of premature opioid-related mortality. Addiction. 2014;109(9):1482–8.PubMedPubMedCentralCrossRef
10.
Dart RC, Severtson SG, Bucher-Bartelson B. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(16):1573–4.PubMed
11.
Paulozzi LJ, Budnitz DS, Xi YL. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15(9):618–27.PubMedCrossRef
12.
Smolina K, Gladstone E, Morgan SG. Determinants of trends in prescription opioid use in British Columbia, Canada, 2005–2013. Pharmacoepidemiol Drug Saf. 2016;25(5):553–9.PubMedCrossRef
13.
Morin KA, Eibl JK, Franklyn AM, Marsh DC. The opioid crisis: past, present and future policy climate in Ontario, Canada. Subst Abuse Treat Prev Policy. 2017;12:1–7.CrossRef
14.
Fentanyl-Detected Illicit Drug Overdose Deaths January 1, 2012 to September 30, 2017. In: Edited by Service BCs. Burnaby: Ministry of Public Safety and Solicitor General; 2017.
15.
Alberta Health. Opioids and Substances of Misuse: Alberta Report, 2017 Q1. Government of Alberta: Alberta; 2017.
16.
Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(14):1372–3.
17.
18.
19.
20.
Service BC. Fentanyl-detected illicit drug overdose deaths January 1, 2012 to March 31, 2018. Kingsway, Burnaby: Ministry of Public Safety and Solicitor General; 2018.
21.
22.
Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S. Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology. 1976;44(5):398–401.PubMedCrossRef
23.
Sporer KA, Dorn E. Heroin-related noncardiogenic pulmonary edema - a case series. Chest. 2001;120(5):1628–32.PubMedCrossRef
24.
25.
Duberstein JL, Kaufman DM. Clinical study of an epidemic of heroin intoxication and heroin-induced pulmonary edema. Am J Med. 1971;51(6):704–+.PubMedCrossRef
26.
Nath SS, Tripathi M, Pandey C, Rao B. Naloxone-induced pulmonary edema: a potential cause of postoperative morbidity in laparoscopic donor nephrectomy. Indian J Med Sci. 2009;63(2):72–5.PubMedCrossRef
27.
Johnson C, Mayer P, Grosz D. Pulmonary-edema following naloxone administration in a healthy orthopedic patient. J Clin Anesth. 1995;7(4):356–7.PubMedCrossRef
28.
Partridge BL, Ward CF. Pulmonary-edema following low-dose naloxone administration. Anesthesiology. 1986;65(6):709–10.PubMedCrossRef
29.
Flacke JW, Flacke WE, Williams GD. Acute pulmonary-edema following naloxone reversal of high-dose morphine anesthesia. Anesthesiology. 1977;47(4):376–8.PubMedCrossRef
30.
Prough DS, Roy R, Bumgarner J, Shannon G. Acute pulmonary-edema in healthy teenagers following conservative doses of intravenous naloxone. Anesthesiology. 1984;60(5):485–6.PubMedCrossRef
31.
Taff RH. Pulmonary-edema following naloxone administration in a patient without heart-disease. Anesthesiology. 1983;59(6):576–7.PubMedCrossRef
32.
Schwartz JA, Koenigsberg MD. Naloxone-induced pulmonary-edema. Ann Emerg Med. 1987;16(11):1294–6.PubMedCrossRef
33.
Michaelis LL, Hickey PR, Clark TA, Dixon WM. Ventricular irritability associated with the use of naloxone hydrochloride. Two case reports and laboratory assessment of the effect of the drug on cardiac excitability. Ann Thorac Surg. 1974;18(6):608–14.PubMedCrossRef
34.
Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf. 2015;14(7):1137–46.PubMedCrossRef
35.
Cuss FM, Colaco CB, Baron JH. Cardiac-arrest after reversal of effects of opiates with naloxone. Br Med J. 1984;288(6414):363–4.CrossRef
36.
37.
Buajordet I, Naess A-C, Jacobsen D, Brors O. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med. 2004;11(1):19–23.PubMedCrossRef
38.
Sivilotti MLA. Flumazenil, naloxone and the “coma cocktail”. Br J Clin Pharmacol. 2016;81(3):428–36.PubMedCrossRef
39.
40.
Gaddis GM, Watson WA. Naloxone-associated patient violence - an overlooked toxicity. Ann Pharmacother. 1992;26(2):196–8.PubMedCrossRef
41.
Cook S, Moeschler O, Michaud K, Yersin B. Acute opiate overdose: characteristics of 190 consecutive cases. Addiction. 1998;93(10):1559–65.PubMedCrossRef
42.
Caudarella A, Dong HR, Milloy MJ, Kerr T, Wood E, Hayashi K. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016;162:51–5.PubMedPubMedCentralCrossRef
43.
Seidler D, Stuhlinger GH, Fischer G, Woisetschlaeger C, Berzlanovich A, Schmid R, Hirschl MM, Laggner AN. After antagonization of acute opiate overdose: a survey at hospitals in Vienna. Addiction. 1996;91(10):1479–87.PubMedCrossRef
44.
Klassen D. Overdose recognition and response in the BC Take Home Naloxone Program; 2016.
45.
Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte CO, Orkin AM, Sawyer KN, Donnino MW. Part 10: special circumstances of resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(suppl 2):S501–18.PubMedCrossRef
46.
Connors NJ, Nelson LS. The evolution of recommended naloxone dosing for opioid overdose by medical specialty. J Med Toxicol : official journal of the American College of Medical Toxicology. 2016;12(3):276–81.CrossRef
47.
Evans JM, Hogg MIJ, Lunn JN, Rosen M. Degree and duration of reversal by naloxone of effects of morphine in conscious subjects. Br Med J. 1974;2(5919):589–91.PubMedPubMedCentralCrossRef
48.
Schumann H, Erickson T, Thompson TM, Zautcke JL, Denton JS. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin Toxicol. 2008;46(6):501–6.CrossRef
49.
Christenson J, Etherington J, Grafstein E, Innes G, Pennington S, Wanger K, Fernandes C, Spinelli JJ, Gao M. Early discharge of patients with presumed opioid overdose: development of a clinical prediction rule. Acad Emerg Med. 2000;7(10):1110–8.PubMedCrossRef
50.
Sutter ME, Gerona RR, Davis MT, Roche BM, Colby DK, Chenoweth JA, Adams AJ, Owen KP, Ford JB, Black HB, et al. Fatal fentanyl: one pill can kill. Acad Emerg Med. 2017;24(1):106–13.PubMedCrossRef
51.
Kerr D, Kelly A-M, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009;104(12):2067–74.PubMedCrossRef
52.
Kelly AM, Kerr D, Dietze P. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose - reply. Med J Aust. 2005;182(8):427–+.
53.
Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care. 2009;13(4):512–5.PubMedCrossRef
54.
CADTH. Intranasal and intramuscular naloxone for opioid overdose in the pre-hospital setting: a review of comparative clinical and cost-effectiveness, and guidelines. In: CADTH rapid response report: summary with critical apprasial. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2017.
55.
56.
Stolbach A, Traub SJ, J G. Acute opioid intoxication in adults. Waltham: Up to Date; 2016.
57.
Kuhlman JJJ, McCaulley R, Valouch TJ, Behonick GS. Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. J Anal Toxicol. 2003;27(7):499–504.PubMedCrossRef
58.
Jones TS, Krzywicki L, Maginnis J, Jones NL, Weiskopf R, Reid M, Schmidt C, Fiedler J, Topolski JM, Graham M, et al. Nonpharmaceutical fentanyl-related deaths - multiple states, April 2005-March 2007 (Reprinted MMWR, vol 57, pg 793-796, 2008). Jama-J Am Med Assoc. 2008;300(13):1512–3.CrossRef
59.
Martin TL, Woodall KL, McLellan BA. Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances, of death in 112 cases (2002-2004). J Anal Toxicol. 2006;30(8):603–10.PubMedCrossRef
60.
Willman MW, Liss DB, Schwarz ES, Mullins ME. Do heroin overdose patients require observation after receiving naloxone? Clin Toxicol. 2017;55(2):81–7.CrossRef
61.
Strang J, McDonald R, Tas B, Day E. Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures? Addiction. 2016;111(4):574–82.PubMedCrossRef
62.
Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus. 2015;36(2):240–53.PubMedPubMedCentralCrossRef
63.
Chou R, Korthuis P, McCarty D, et al. Management of suspected opioid overdose with naloxone in out-of-hospital settings: a systematic review. Ann Intern Med. 2017;167(12):867–75.PubMedCrossRef
64.
Moher D, Liberati A, Tetzlaff J, Altman DG. The PG: Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.PubMedPubMedCentralCrossRef
65.
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–12.PubMedCrossRef
66.
Kim HK, Nelson LS. Reversal of opioid-induced ventilatory depression using low-dose naloxone (0.04 mg): a case series. J Med Toxicol. 2016;12(1):107–10.PubMedCrossRef
67.
Canada Go. Joint statement of action to address the opioid crisis: Government of Canada; 2016.
68.
Government of Canada. Joint Statement of Action to Address the Opioid Crisis. Ottawa: Government of Canada; 2016.
Metadata
Title
Naloxone interventions in opioid overdoses: a systematic review protocol
Authors
Lindsay Victoria Shaw
Jessica Moe
Roy Purssell
Jane A. Buxton
Jesse Godwin
Mary M. Doyle-Waters
Penelope M. A. Brasher
Jeffrey P. Hau
Jason Curran
Corinne M. Hohl
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2019
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-019-1048-y

Other articles of this Issue 1/2019

Systematic Reviews 1/2019 Go to the issue

Letter

Maintaining relevance in HIV systematic reviews: an evaluation of Cochrane reviews

Protocol

Evidence on point-of-care diagnostics for assessment of nutritional biochemical markers as an integral part of maternal services in low- and middle-income countries: systematic scoping review protocol

Methodology

A comparison between two recommendations to conduct and report systematic reviews on drug’s safety

Protocol

Interpersonal psychotherapy for perinatal women: a systematic review and meta-analysis protocol

Protocol

Experiential peer support and its effects on desistance from delinquent behavior: protocol paper for a systematic realist literature review

Protocol

Prevalence and comorbidity of autism spectrum disorder in Spain: study protocol for a systematic review and meta-analysis of observational studies